EUCTR2006-006760-28-AT进行中（未招募）不适用
Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to Age-Related Macular Degeneration - KAV-Ranibizumab
udwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie0 个研究点目标入组 45 人开始时间: 2007年5月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The study population will consist of male and female patients > 50 years of age with subfoveal choroidal neovascularization (CNV) secondary to AMD.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Patients who have a BCVA of < 33 letters (approximately 20/200) in both eyes
- •·Prior treatment in the study eye with verteporfin, external-beam radiation therapy, vitrectomy, submacular surgery, other surgical intervention for AMD, or transpupillary thermotherapy
- •·Previous or current intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye
- •·Focal laser photocoagulation (juxta-, extra- or subfoveal) in the study eye
研究者
相似试验
已完成
4 期
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)Polypoidal Choroidal VasculopathyAge-related Macular DegenerationNCT01846273Novartis Pharmaceuticals321
招募中
2 期
A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.Diabetic Macular OedemaEye - Diseases / disorders of the eyeMetabolic and Endocrine - DiabetesDiabetic RetinopathyACTRN12611000063910ovartis40
已完成
不适用
Comparison of inravitreal ranibizumab therapy with and without laser photocoagulation for diabetic macular edema.diabetic macular edemaJPRN-UMIN000024697Tokyo Women's Medical University100
进行中（未招募）
1 期
Ranibizumab (Lucentis) for treatment of Uveitic Macular Oedema (LIMO)veitic Macular OedemaMedDRA version: 20.0 Level: PT Classification code 10046851 Term: Uveitis System Organ Class: 10015919 - Eye disordersMedDRA version: 20.1 Level: PT Classification code 10058202 Term: Cystoid macular oedema System Organ Class: 10015919 - Eye disordersEUCTR2011-001869-41-GBMoorfields Eye Hospital NHS Foundation Trust20
进行中（未招募）
1 期
The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation - Management and control of corneal neovascularisation using LucentisCorneal neovesselsEUCTR2010-018673-37-GBniversity of Nottingham6